Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer

British Journal of Cancer volume 129, pages 1176–1183 (2023)Cite this article

Subjects

Abstract

Background

This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs). We also characterised HER2 expression statuses in CRCs focusing on their intratumoral heterogeneity and alterations in metastatic lesions to establish practical HER2 status assessment.

Methods

We evaluated 1009 CRCs for HER2 expression and HER2 amplification by immunohistochemistry and FISH, respectively, and correlated the results to clinicopathological and molecular data. For HER2-positive tumours, HER2 expression in metastatic lesions was also assessed.

Results

Twenty-five HER2-amplified (2.5%) and 46 HER2-low tumours (4.6%) were identified. HER2-amplified tumours consistently lacked a mucinous component and HER2-low tumours tended to be in the right colon, but no other clinicopathological features were noted. KRAS, NRAS or BRAF mutations were detected in only two HER2-amplified tumours (8%), whereas 23 HER2-low tumours (50%) had one of these mutations. Most HER2-amplified and HER2-low tumours showed a homogeneous or mosaic HER2 expression pattern and a clustered heterogeneous expression pattern was rather rare. HER2 expression was maintained in most metastatic lesions in both HER2-amplified (93%) and HER2-low tumours (81%).

Conclusions

These results suggest that biopsy-based assessment of primary lesions is appropriate for the identification of CRC patients eligible for systemic HER2-targeted therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: HER2 expression pattern classification.
Fig. 2
Fig. 3: HER2 expression in primary and metastatic tumours.
Fig. 4: HER2 expression status in primary and metastatic tumours.
Fig. 5: HER2 mRNA expression by HER2 immunohistochemistry (IHC)/FISH status.

Similar content being viewed by others

Data availability

All data and materials generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  2. Fabregas JC, Ramnaraign B, George TJ. Clinical updates for colon cancer care in 2022. Clin Colorectal Cancer. 2022;21:198–203.

    Article  PubMed  Google Scholar 

  3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.

    Article  CAS  PubMed  Google Scholar 

  4. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32.

    Article  PubMed  Google Scholar 

  5. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  6. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111:1977–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481–91.

    Article  CAS  PubMed  Google Scholar 

  9. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.

    Article  CAS  PubMed  Google Scholar 

  11. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89.

    Article  CAS  PubMed  Google Scholar 

  12. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:329–59.

    Article  Google Scholar 

  15. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145:3414–24.

    Article  CAS  PubMed  Google Scholar 

  17. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140:1345–63.

    Article  PubMed  Google Scholar 

  19. Kanayama K, Imai H, Yoneda M, Hirokawa YS, Shiraishi T. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: a comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci. 2016;107:536–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE. 2014;9:e98528.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yagisawa M, Sawada K, Nakamura Y, Fujii S, Yuki S, Komatsu Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2020;20:113–20.

  22. Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124:1358–73.

    Article  CAS  PubMed  Google Scholar 

  23. Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018;144:2275–81.

    Article  CAS  PubMed  Google Scholar 

  24. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol. 2011;136:864–71.

    Article  PubMed  Google Scholar 

  25. Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int. 2016;66:313–24.

    Article  PubMed  Google Scholar 

  26. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105–22.

    Article  CAS  PubMed  Google Scholar 

  27. Sekine S, Gutierrez PJ, Lan BY, Feng S, Hebrok M. Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology. 2007;45:361–8.

    Article  CAS  PubMed  Google Scholar 

  28. Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS ONE. 2016;11:e0151865.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22:518–25.

    Article  CAS  PubMed  Google Scholar 

  30. Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11:2474–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee HJ, Kim JY, Park SY, Park IA, Song IH, Yu JH, et al. Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Am J Clin Pathol. 2015;144:570–8.

    Article  PubMed  Google Scholar 

  32. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol. 2013;85:45–81.

    Article  PubMed  Google Scholar 

  33. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112:1103–13.

    Article  CAS  PubMed  Google Scholar 

  34. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;55:548–55.

    Article  CAS  PubMed  Google Scholar 

  35. Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:198–205.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. Hitoshi Ichikawa, Dr. Masahiro Gotoh, Ms. Sachiko Miura, Ms. Toshiko Sakaguchi, Ms. Chizu Kina, Ms. Maiko Matsuda, Ms. Yoko Shimada, Ms. Sachiyo Mitani and Mr. Hiroki Kakishima for their skilful technical assistance.

Funding

None.

Author information

Authors and Affiliations

  1. Division of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan

    Taiki Hashimoto, Junpei Yonemaru, Tomoaki Naka, Yasushi Yatabe & Shigeki Sekine

  2. Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan

    Daisuke Takayanagi, Erika Machida, Takashi Kohno & Kouya Shiraishi

  3. Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan

    Daisuke Takayanagi

  4. Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan

    Daisuke Takayanagi

  5. Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan

    Kengo Nagashima

  6. Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan

    Yasushi Yatabe & Shigeki Sekine

  7. Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan

    Yukihide Kanemitsu

  8. Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan

    Ryuji Hamamoto

  9. Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    Atsuo Takashima

  10. Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan

    Kouya Shiraishi

Authors
  1. Taiki Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Takayanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junpei Yonemaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoaki Naka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kengo Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erika Machida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasushi Yatabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yukihide Kanemitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ryuji Hamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Atsuo Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kouya Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shigeki Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TH, KS, EM, TK and SS carried out experiments and analysed data. TH, JY, TN, YY and SS performed histological analyses. KN conducted the statistical analysis. TH and SS wrote the manuscript. DT, YK and AT provided clinicopathological and mutation data. RH reviewed the paper. All authors provided critical revisions of the final manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shigeki Sekine.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the National Cancer Center Tokyo, Japan. The study was performed in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashimoto, T., Takayanagi, D., Yonemaru, J. et al. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. Br J Cancer 129, 1176–1183 (2023). https://doi.org/10.1038/s41416-023-02382-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-023-02382-z

This article is cited by

Search

Advanced search

Quick links